Breaking News Instant updates and real-time market news.

INO

Inovio

$4.63

0.11 (2.43%)

08:17
11/29/17
11/29
08:17
11/29/17
08:17

Inovio: VGX-3100 data showed immune correlates, signatures predictive of success

Inovio Pharmaceuticals announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success. VGX-3100, Inovio's lead product now in a pivotal phase 3 trial, would be the first non-surgical treatment for HPV-associated high grade cervical dysplasia which frequently progresses to cancer. Details of the new biomarker and immunologic data are highlighted in the peer-reviewed journal Clinical Cancer Research in the article, "Clinical and Immunologic Biomarkers for Histologic Regression of High-grade Cervical Dysplasia and Clearance of HPV-16 and HPV-18 after Immunotherapy," by Inovio and its academic collaborators. In this paper, Inovio has identified biomarker signatures which predicted success of VGX-3100 treatment as early as two weeks after the completion of treatment which was a full 22 weeks prior to the formal efficacy assessment. The company believes these biomarkers will aid physicians in guiding patient care during VGX-3100 treatment, and is pursuing the confirmation of these predictions in its phase 3 program. Inovio is also researching pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product. Dr. J. Joseph Kim, President and CEO, said: "Inovio will transform the treatment of HPV-associated disease with the first immunotherapies to treat both pre-cancer and cancer caused by HPV which infects more than 70% of sexually active adults. Today's advancement in discovering a successful treatment biomarker moves us closer to that goal."

  • 29

    Nov

  • 06

    Dec

INO Inovio
$4.63

0.11 (2.43%)

09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
10/06/17
SBSH
10/06/17
NO CHANGE
Target $10
SBSH
Buy
Zika data supportive of Inovio's platform, says Citi
The Phase 1 trial data for the company's Zika vaccine, published this week in the New England Journal of Medicine, are supportive for Inovio's platform beyond the immunogenicity data, Beatty tells investors in a research note. Inovio's platform may have the potential to generate functional antibodies in nearly 100% of people receiving a vaccine, which could also be useful in oncology if good antigen and tumor matches are made, Beatty adds. He believes the data support the view that Inovio is a leader in infectious disease vaccines. The analyst keeps a Buy rating on the shares with a $10 price target.
10/18/17
RBCM
10/18/17
INITIATION
RBCM
Outperform
Inovio initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler initiated Inovio with an Outperform and $11 price target saying Phase III asset VGX-3100 has potential to be the first non-surgical approach for the treatment of HPV-driven cervical pre-cancers. Eckler also believes Inovio's early immuno-oncology platform also offer significant upside if any of the ongoing Phase1/Phase trials generate encouraging results.
10/18/17
10/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Neutral at Janney Capital. 2. Inovio (INO) initiated with an Outperform at RBC Capital. 3. Carrizo Oil & Gas (CRZO) reinstated with a Neutral at Goldman Sachs. 4. Goodrich Petroleum (GDP) assumed with a Buy at Seaport Global. 5. Krystal Biotech (KRYS) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

GTY

Getty Realty

$28.10

0.08 (0.29%)

05:22
12/12/17
12/12
05:22
12/12/17
05:22
Initiation
Getty Realty initiated  »

Getty Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.14

0.84 (3.77%)

05:16
12/12/17
12/12
05:16
12/12/17
05:16
Recommendations
Mallinckrodt analyst commentary  »

Mallinckrodt management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SFIX

Stitch Fix

$23.98

0.38 (1.61%)

05:13
12/12/17
12/12
05:13
12/12/17
05:13
Initiation
Stitch Fix initiated  »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

WEB

Web.com

$23.00

1.2 (5.50%)

05:10
12/12/17
12/12
05:10
12/12/17
05:10
Downgrade
Web.com rating change  »

Web.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNPS

Synopsys

$89.56

-0.95 (-1.05%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
Synopsys rating change  »

Synopsys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$41.38

0.75 (1.85%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
SS&C rating change  »

SS&C downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$123.09

1.28 (1.05%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
ServiceNow rating change  »

ServiceNow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RNG

RingCentral

$47.55

-0.75 (-1.55%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
RingCentral rating change  »

RingCentral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$40.35

-0.1 (-0.25%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Q2 Holdings rating change  »

Q2 Holdings downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

QLYS

Qualys

$59.00

0.55 (0.94%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Qualys rating change  »

Qualys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$61.44

-0.26 (-0.42%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
PTC rating change  »

PTC downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWR

New Relic

$60.00

2.77 (4.84%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
New Relic rating change  »

New Relic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

TYPE

Monotype Imaging

$24.40

-0.2 (-0.81%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Monotype Imaging rating change  »

Monotype Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MODN

Model N

$16.00

0.05 (0.31%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Model N rating change  »

Model N downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIME

Mimecast

$28.02

-0.72 (-2.51%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Mimecast rating change  »

Mimecast downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMPV

Imperva

$41.85

0.3 (0.72%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$48.95

0.07 (0.14%)

05:03
12/12/17
12/12
05:03
12/12/17
05:03
Downgrade
GoDaddy rating change  »

GoDaddy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$42.22

0.27 (0.64%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Jan

CSGP

CoStar Group

$290.50

-1.84 (-0.63%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
CoStar Group rating change  »

CoStar Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

CHKP

Check Point

$105.85

1.07 (1.02%)

05:01
12/12/17
12/12
05:01
12/12/17
05:01
Downgrade
Check Point rating change  »

Check Point downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CUDA

Barracuda

$27.61

0.08 (0.29%)

05:00
12/12/17
12/12
05:00
12/12/17
05:00
Downgrade
Barracuda rating change  »

Barracuda downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$174.31

0.74 (0.43%)

04:59
12/12/17
12/12
04:59
12/12/17
04:59
Downgrade
Adobe rating change  »

Adobe downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SAIL

SailPoint Technologies

$14.83

-0.61 (-3.95%)

04:56
12/12/17
12/12
04:56
12/12/17
04:56
Initiation
SailPoint Technologies initiated  »

SailPoint Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELGX

Endologix

$5.77

0.1 (1.76%)

04:55
12/12/17
12/12
04:55
12/12/17
04:55
Initiation
Endologix initiated  »

Endologix assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

, SQ

Square

$38.30

0.21 (0.55%)

04:55
12/12/17
12/12
04:55
12/12/17
04:55
Conference/Events
Credit Suisse finance analysts hold an analyst/industry conference call »

Financial Analysts Paul…

BTC

Bitcoin

SQ

Square

$38.30

0.21 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.